within Pharmacolibrary.Drugs.ATC.C;

model C04AE02
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.055,
    Cl             = 0.0008950000000000001,
    adminDuration  = 600,
    adminMass      = 30 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.108,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0027166666666666667,
    Tlag           = 600,            
    Vdp             = 0.233,
    k12             = 101,
    k21             = 101
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C04AE02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Nicergoline is an ergot alkaloid derivative used mainly to treat cognitive, neurological and vascular disorders related to aging, such as dementia and cerebrovascular insufficiency. It acts as an alpha-adrenergic antagonist, improves cerebral blood flow, and has neuroprotective properties. Nicergoline was widely used in Europe and some Asian countries, but its use is now limited or restricted in several countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers (both sexes), following single oral dose administration.</p><h4>References</h4><ol><li><p>Ezan, E, et al., &amp; Grognet, JM (2001). Immunoassays for the detection of nicergoline and its metabolites in human plasma. <i>Journal of pharmaceutical and biomedical analysis</i> 25(1) 123–130. DOI:<a href=\"https://doi.org/10.1016/s0731-7085(00)00501-x\">10.1016/s0731-7085(00)00501-x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11274866/\">https://pubmed.ncbi.nlm.nih.gov/11274866</a></p></li><li><p>Böttiger, Y, et al., &amp; Bertilsson, L (1996). Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans. <i>British journal of clinical pharmacology</i> 42(6) 707–711. DOI:<a href=\"https://doi.org/10.1046/j.1365-2125.1996.00471.x\">10.1046/j.1365-2125.1996.00471.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8971425/\">https://pubmed.ncbi.nlm.nih.gov/8971425</a></p></li><li><p>Kohlenberg-Müller, K, et al., &amp; Schaffler, K (1991). [Comparative studies on the bioavailability of nicergoline from two different steady-state preparations]. <i>Arzneimittel-Forschung</i> 41(7) 728–731. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1772461/\">https://pubmed.ncbi.nlm.nih.gov/1772461</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C04AE02;
